BDRX - What's Going On With Biodexa Pharmaceuticals Stock? | Benzinga
Biodexa Pharmaceuticals (NASDAQ:BDRX) stock is trading higher. The company on Tuesday announced progress towards the treatment of Familial Adenomatous Polyposis.
What Happened: Biodexa, a clinical-stage biopharmaceutical company dedicated to acquiring and developing innovative solutions for diseases with unmet medical needs, has announced positive statistically significant findings from the Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis.
During the trial, patients were divided into three groups of 10, receiving different doses of the treatment over 12 months. Endoscopic exams were conducted at the start and after six months to evaluate safety, tolerability and changes in polyp size.
The results of the experiment showed eRapa, an oral tablet formulation of rapamycin, appeared safe and well-tolerated with a significant 24% reduction in the total ...